Tempest Therapeutics, Inc. Common Stock (TPST) is a publicly traded Healthcare sector company. As of May 21, 2026, TPST trades at $1.98 with a market cap of $26.95M and a P/E ratio of -0.29. TPST moved +5.62% today. Year to date, TPST is +31.91%; over the trailing twelve months it is -44.48%. Its 52-week range spans $1.20 to $10.34. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces TPST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tempest Achieves 100% CR in TPST-2003 Trials and Secures AGCTC Manufacturing Partner: Tempest Therapeutics reported 100% complete response in 15 CAR-T-naïve patients across its REDEEM-1 and POEMS-1 Phase 1/2a TPST-2003 trials and named Cincinnati Children’s AGCTC lead manufacturing partner. The company ended Q1 with $1.8 million cash, logged a $27.7 million net loss, and appointed Andrew Fang as Head of Business Development.
| Metric | Value |
|---|---|
| Price | $1.98 |
| Market Cap | $26.95M |
| P/E Ratio | -0.29 |
| EPS | $-6.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.34 |
| 52-Week Low | $1.20 |
| Volume | 330 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.26M |
| Gross Margin | 0.00% |
1 analysts cover TPST: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.